Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ACTC - bought a small amount today. These low-volume declines during quiet periods seem to be merely impatience .. taking advantage often works out.
I'm still confused, given their positive India trial results, why it is so hard to get funding or a partner? The methodology of clinical trials is NOT complicated ... to be blunt, folks who got the drug died less than normal (at a statistically significant level). Such confirmation of hypothesis is the nature of scientific evidence!
To be more precise, what matters more their treatment being proved effective, the potential profits, the current marketcap/enterprise value, and the cost to bring to market? (Of course, we are dealing with probabilities and uncertainties, but the basic idea stands.)
In this regard, is there one part of the equation I'm missing ... such as huge cost to bring to market because of (potential) exective compensation? Something like that would make sense...
Alternatively, perhaps the market indeed cares more about share structure and the exchange. If so, the explanation leaves me thinking... is the market really this dumb/inefficient? It's like not going outside on a beautiful cloudless day, because the forecast last week said it might be rainy ... the actual reality/result should be considered more important than factors that might otherwise correlate with a good result.
As a third set of alternatives, perhaps there is skepticism about the trials being in India? Or back to my old issue there was not a random control group? Have clinical trials been manipulated in the past to warrant this skepticism? That would make sense, but I don't have the knowledge.
Essentially, I'm trying to understand if the share price is rational from a fundmentals persective... if yes, then what are the fundamantals I missed? If no, then I'll have to be more careful that there are other factors to consider than trying to find undervalued companies... perhaps the solution is to ignore any company that needs financing, despite the potential?
Sorry for this mini-rant but needed to get these thoughts off my chest ... lol!
Yes, I bought some at 80 cents and then a lot more a 51 cents ...so some a double and some a triple!!
I sold some around $1.10 (and one swing trade) but still holding a very large chunk of shares so this is certainly helping out my portfolio!
Perhaps ADXS will get some sympathy buying soon!?
This has not been mentioned ... imagine when VODWIZ goes live how much exposure to new investors! Currently, we are a bit stuck as folks don't want to sell, but no new buyers.
Would it be a good idea to suggest a link on VODWIZ to the HHSE (and NTEK) webpages?
NWBO ... mystery rally!
Perhaps there is delay with retailers because of the recent upgrade to the NVIDIA processor?
I'm not up to speed on all the details, so appologies if this has been discussed already.
What devices are there to play that content on a 4K TV?
Turns out then, that bundling a Nuvola (with VODWIZ) was a good strategic move for Seiki... the "bundle" differentiates them from the compeition... folks are going to want 4K content for their TVs and will pay more accordingly!
Not yet ...
Based on the trading today, it seems the few of us on the message board are the only one's that have made the connection. This confirms, IMO, we are still very much under the market radar which means great potential as this news is digested ... great things ahead!
I've been accumulating HHSE for years ... and I'm more excited now than ever!
Yes, the dots are connected .... early 4K adopters will be rushing to VODWIZ to experience (and show off) their new technology! How awesome for our little HHSE!
1. SEIKI TVs to bundle with NUVOLA4K
http://finance.yahoo.com/news/nanotech-partners-seiki-digital-deliver-130200381.html
2. NUVOLA4K bundled with VODWIZ
https://www.nuvola4k.com/techspec.php
3. VODWIZ movies being mastered in 4K
http://hannoverhousemovies.blogspot.com/2013/07/a-brave-new-media-world.html
NTEK/VODWIZ ... NUVOLA4K previously confirmed by NVDIA, now to be bundled with SEIKI TVs:
http://finance.yahoo.com/news/nanotech-partners-seiki-digital-deliver-130200381.html
VODWIZ going to be bundled in NUVOLA4K.
https://www.nuvola4k.com/techspec.php
Connecting the dots ... pretty much confirmed that new SEIKI TV owners will be exposed to VODWIZ ... not bad for our little HHSE!
HHSE blog mentions titles are indeed being remastered in 4K. I've not seen this confirmed independently, but even if there are no 4K titles the exposure is helpful ... BUT, if early adopters rush to VODWIZ to showcase their new TVs, this could be a very big deal...
http://hannoverhousemovies.blogspot.com/2013/07/a-brave-new-media-world.html
Thanks ... I'm still thinking about individual commodites but the overll resource sector sure seems as bottoming to me... but I thought the same last year!
I contacted Eric, Fred and Garret ... I'm not sure their responsiveness, but hopefully they read it... thanks!
I have some feedback for the page. What is the best way to contact Eric and Fred about this?
Specifically, although I think the graphic looks professional and I love the idea of a free movie (to drive traffic and new users) there is one important marketing improvement:
Folks who stumble across the page might NOT KNOW it is for RENTNG MOVIES. Some might infer from the name VODWIZ but others might associate the name with cable TV and think it is to rent a cable box or something like that. Additionally, they'll next see Roku and think 'what is that' and further think the page is not for them.
Netflix PROMINENTLY explains on the homepage:
"Watch TV Shows and Movies, anytime"
That's fine if you aren't interested in those movies. I'm more curious, however, what you think from a shareholder perspective. Accordingly, these additional factors might be worthy of consideration:
1. Management has announced here are still lots of movies to come so a much bigger selection is anticipated.
2. TUFI (total upfront investment) is minimal so there is not much risk.
3. Netflix has a marketcap of $14Billion which is 1,000X HHSE ...thus, even if the portal could do only 1/1000 as well that would justify $14M extra marketcap.
4. There could very well be a significant early adopter effect as 4K sales ramp up.
Thus, from a financial perspective, it looks pretty good, right? As a shareholder, I'm pretty excited to see what develops here!
For what it's worth, I feel your pain!
Incidentally, this might be help for tracking rare earth price trends... I'm not sure which are the most important heavy ree (being lazy at the moment) but you can see some have recovered a bit and others not. I'm sure we'll certainly recover here, which -- in turn -- will help the stocks...
Perhaps you've seen this already?
http://www.metal-pages.com/metalprices/rareearths/
We don't always see eye-to-eye but thank you as well!
Thanks also!
Thanks for the help ... this board is great!!
Deceptz showing on Redbox as distributed by Phase 4 Films. I think this is a mistake as Deceptz does not show on P4 catalog and -- with my own eyes -- I saw Hannover House logo on Deceptz at Walmart ... not doubting that.
Just curious, is this an error or some kind of partnership? Otherwise, perhaps this should be corrected.
http://www.redbox.com/movies/deceptz
http://www.phase4films.com/cs.aspx?titleSearch=Deceptz&p=catalog
Should have followed my gut and bought some ... up quite decently.
Yes, we are very lucky to know about about it here! It's too bad for the millions of Walmart shoppers that might not have seen your post (or searched elsewhere) won't know about this release until they see it on the shelves... thanks though for letting us know about the opportunity.
Thanks ... I'm a little obsessed on this point but being in Safeway is huge for us!
Hi Robin,
Next time you are at Safeway, would you mind taking a photo of Cabana on the shelves there? It would be interesting to see the placement... hopefully I'm not imposing!
Thanks for that great post ... every single item looks to be great potential and the current share price hardly factors in any of them!
The best part is that many/most of these are verifiable!
I responded too soon ... thanks and my appologies for any misunderstanding.
I've not had the time to see that video but I'll be sure as soon as I have the chance... I like what I see here, but -- of course -- want to be solid as possible on my DD.
Thanks ... of course, I'll be sure to continue investigating as there seems a LOT of potential here.
Its ironic (and disappointing) that some feel the need to defend their investments by only reinforcing the positive, when genuine discussion of this innovative company would probably help the share price much more!
Anyway, they win ... the question is dropped.
I'm already invested ... why would I wait for the stock to be 10 times higher when I can get in before the crowd? Of course, to do this I need to be confident in my DD, which is why I'm asking these questions!
Isn't that the purpose here ... to educate and be educated?
I'm just trying to get a feel for the significance of this news. Have we inched yet closer or is the news today, or from a scientific perspective, is this a huge deal?
I'm very curious any additional insights in the science!
So I guess you are VERY confident this will pass human trials? I tend also to be optimistic but if the science is so definitive then why hasn't the share price skyrocketed ... is the market really that short-sighted if the evidence is indeed so obvious?
In other studies, are not animals also selected based on similarity to humans as well? Or as you say, is cancer fundamentally different to other studies that we can be much more optimistic here ... I'm asking as I'm not that familiar with other animal studies and want to leverage the expertise here.
If the market is not appreciating the science, then we should not be so flippant but deeply consider these details as the potential return is huge! Isn't such consideration much more important than the daily share price movement?
I'm curious opinions on these animal studies?
The majority of successful animal studies fail to pass human trials ... yet, in this case, I think we can be optimistic ... although a monkey or mouse immune system might be different, proking the immune system of ANY organism to attack cancer seems to be a hugely innovative accomplishment. It seems to me such achievement should be adaptable to different organisms/animals.
I do not have a background in biology, however, so I'm wondering what the experts think ... may the success in animal studies for INO be considered more optimistically than the successes of other animal studies?
Would be nice to have more of this type of discussion on fundamentals versus fixation on share-price fluctuations.
INO - back up 9% today on news of potential 'universal' cancer therapy.
"Inovio Pharmaceuticals' Potent hTERT DNA Cancer Vaccine Shows Potential to Reduce Tumors and Prevent Tumor Recurrence"
http://ih.advfn.com/p.php?pid=nmona&article=58525653&symbol=INO
BLUE BELL, Pa., July 24, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study with two animal models, Inovio's hTERT (human telomerase reverse transcriptase) DNA cancer vaccine administered with Inovio's CELLECTRA® adaptive electroporation delivery technology generated robust and broad immune responses, broke the immune system's tolerance to its self-antigens, induced T-cells with a tumor-killing function, and increased the rate of survival. Because high levels of hTERT expression are found in 85% of human cancers, regardless of type, Inovio's cancer candidate holds the potential to perform as a "universal" cancer therapeutic based on these early but unprecedented results. Following this strong preclinical data, Inovio plans to advance its synthetic hTERT cancer vaccine, INO-1400, into clinical trials in 2014.
These results appear in the American Association for Cancer Research journal, Cancer Immunology Research, in a paper entitled: "Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity," authored by Inovio researchers and collaborators.
Dr. J. Joseph Kim, Inovio's president and CEO, said: "Inovio has demonstrated in multiple published human studies that our synthetically optimized DNA vaccines delivered with our CELLECTRA delivery system generate best-in-class T-cell immune responses. Here we show that in monkeys our hTERT DNA cancer vaccine generated T-cell immune responses more than 18-fold higher than the previous best results of a peer's hTERT therapeutic vaccine, which was also a DNA vaccine delivered with electroporation. We are particularly enthusiastic about our vaccine's potential use as a "universal" cancer therapeutic, given that hTERT is present in the vast majority of cancer types yet rare in normal cells. We plan to develop INO-1400 to treat breast and lung cancers and then expand to other cancer types. This hTERT therapy adds to a growing Inovio oncology franchise spearheaded by our phase II candidate, VGX-3100 for treating HPV-related pre-cancers and cancers, as well as our near clinical INO-5150 to treat prostate cancer."
Data from both murine and human systems over the past 10 years have demonstrated that TERT-specific cytotoxic T-lymphocytes (CTLs) can recognize and kill TERT-expressing tumor cells in multiple types of cancers. In fact, previous research has shown that breast cancer patients who mounted an hTERT-specific CTL response exhibited significantly longer rates of survival. However, the immune system's tolerance of cancer cells and their associated antigens produced in the body, which exists to prevent autoimmune diseases, often restricts the immune system's antitumor response. A major challenge for cancer vaccine development has been to develop approaches to break this tolerance in tumor-bearing hosts. Recent advances in our understanding of antigen presentation and tolerance have led Inovio to create this synthetic DNA vaccine targeting the hTERT antigen.
Inovio constructed a highly optimized synthetic DNA vaccine with multiple proprietary features. Using its novel consensus design approach, two differentiating mutations were incorporated in the vaccine sequence to assist T-cells to more readily recognize self-made hTERT antigens and kill the cancer cells to which these antigens are attached (i.e. break tolerance). In addition, Inovio's use of a full length antigen DNA sequence encompasses multiple epitopes (parts of an antigen that are recognized by the immune system), potentially helping the immune system by providing multiple opportunities to overcome a tumor's ability to evade recognition by T-cells.
In the study, Inovio researchers confirmed that vaccination with Inovio's DNA vaccine delivered by adaptive electroporation induced hTERT-specific cellular immune responses with significantly greater T-cell magnitude compared to prior non-Inovio studies. Over four vaccinations there was a significant dose response, showing the value of multiple vaccinations to increase the immune response and highlighting the limitation of alternative technologies that are not amenable to multiple vaccinations such as viral vectors. Vaccination elicited multiple epitopes not only in mice, but also in monkeys, indicating a broad vaccine-induced immune response.
Study results showed that mice vaccinated with Inovio's DNA cancer vaccine and then challenged with a cancerous tumor experienced delayed tumor growth and longer overall survival compared with non-vaccinated mice. Mice first challenged with a tumor and then treated with the hTERT DNA vaccine displayed killing activity of the targeted cancer cells expressing the hTERT antigen, with no killing of normal cells that did not express the hTERT antigen. The treated mice experienced significantly smaller tumors and also longer overall survival. Vaccinated animal results were compared to a control group of animals that did not receive Inovio's DNA cancer vaccine.
In monkeys, whose TERT is 96% similar to human TERT and therefore a highly relevant model for immunotherapeutic vaccine development, the hTERT DNA vaccine elicited strong and broad TERT-specific immune responses and demonstrated the potential to eliminate tumor cells.
Overall, in these studies researchers observed that administration of a synthetic highly optimized hTERT DNA vaccine delivered with electroporation was capable of breaking immune tolerance, and eliciting robust and diverse antigen-specific CTLs, which are responsible for clearing cancerous cells, as well as a potent antitumor response. A favorable safety profile emerged from this study, showing that the vaccine-induced CTLs appeared not to be associated with any major toxicities or organ damage.
The expression of hTERT is thought to correlate with tumor survival and hTERT is associated with 85% of human tumors. Furthermore, there is growing recognition that it may be necessary to target stem cells that produce cancerous cells and recent studies have suggested that cancer stem or stem-like cells also express hTERT. These factors highlight the importance of an effective hTERT-targeting vaccine/immunotherapy and point to the
Hi Malc,
I sent an email ... I was also going to text you but my cell phone died and I lost your number. Could you please send me a text and I'll be sure back up the contact information this time... I'm learning that lesson the hard way!
No volume on US-ticker on this news ... good indication that we are under-the-radar..
exmgf/min.v - my wildcard miner announced financing today at .16 which is above the average shareprice for the last few months ... I'm still bullish, but too bad it's sooo difficult for miners to get much-needed financing.... let's hope the feasibility study can now get done soon.
Interestingly, the bulk of financing is royalty.
http://finance.yahoo.com/news/excelsior-announces-financing-callinan-royalties-103000410.html
"Callinan’s purchase of a royalty on Excelsior’s Gunnison project is welcome news in a battered junior-mining landscape. When it is all said and done, the total investment could equal $22M. By securing a major financing partner, the company has removed a major barrier going forward – whatever the market sentiment, Excelsior is on a much better path now.
Shareholders should appreciate that this financing is largely non-dilutive. One of the advantages that Excelsior had was that when they acquired this huge copper deposit (over 4-billion pounds), it came in with virtually no royalties attached. It is very rare for a project of this size to not be encumbered with royalties. And now Excelsior is playing this trump card through the sale of a royalty.
This financing could suggest that the smart money IS deploying funds for good projects that long ago reached rock-bottom prices. I suspect that firms and investors who have been tracking Excelsior should find this news worthy of further interest.
Generally, royalty companies like Callinan do not invest in projects until at least the feasibility stage. The fact that Callinan is willing to step forward in advance of the Pre-Feasibility can be viewed as a major endorsement of the project and the management team. You can be sure that Callinan did extensive due diligence; obviously they liked what they saw.
And there could be more good news ahead. Management continues to indicate that they are working on a potential transaction of significant scale.
"
I could not find a section on the Apple webpage for their upcoming iWatch ... nothing. That company is a total scam too!!
Discovering truth is not as simple as speculating on one tiny bit of information while ignoring all other relevant details and factors.